These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

283 related items for PubMed ID: 12917408

  • 1. Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity.
    Lu D, Shen J, Vil MD, Zhang H, Jimenez X, Bohlen P, Witte L, Zhu Z.
    J Biol Chem; 2003 Oct 31; 278(44):43496-507. PubMed ID: 12917408
    [Abstract] [Full Text] [Related]

  • 2. Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy.
    Lu D, Jimenez X, Zhang H, Bohlen P, Witte L, Zhu Z.
    Int J Cancer; 2002 Jan 20; 97(3):393-9. PubMed ID: 11774295
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity.
    Zhu Z, Hattori K, Zhang H, Jimenez X, Ludwig DL, Dias S, Kussie P, Koo H, Kim HJ, Lu D, Liu M, Tejada R, Friedrich M, Bohlen P, Witte L, Rafii S.
    Leukemia; 2003 Mar 20; 17(3):604-11. PubMed ID: 12646950
    [Abstract] [Full Text] [Related]

  • 4. Generation of Potent Anti-Vascular Endothelial Growth Factor Neutralizing Antibodies from Mouse Phage Display Library for Cancer Therapy.
    Lai YD, Wu YY, Tsai YJ, Tsai YS, Lin YY, Lai SL, Huang CY, Lok YY, Hu CY, Lai JS.
    Int J Mol Sci; 2016 Feb 05; 17(2):214. PubMed ID: 26861297
    [Abstract] [Full Text] [Related]

  • 5. A recombinant, fully human, bispecific antibody neutralizes the biological activities mediated by both vascular endothelial growth factor receptors 2 and 3.
    Jimenez X, Lu D, Brennan L, Persaud K, Liu M, Miao H, Witte L, Zhu Z.
    Mol Cancer Ther; 2005 Mar 05; 4(3):427-34. PubMed ID: 15767551
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library.
    Zhu Z, Rockwell P, Lu D, Kotanides H, Pytowski B, Hicklin DJ, Bohlen P, Witte L.
    Cancer Res; 1998 Aug 01; 58(15):3209-14. PubMed ID: 9699643
    [Abstract] [Full Text] [Related]

  • 7. Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis.
    Binétruy-Tournaire R, Demangel C, Malavaud B, Vassy R, Rouyre S, Kraemer M, Plouët J, Derbin C, Perret G, Mazié JC.
    EMBO J; 2000 Apr 03; 19(7):1525-33. PubMed ID: 10747021
    [Abstract] [Full Text] [Related]

  • 8. A novel peptide isolated from a phage display library inhibits tumor growth and metastasis by blocking the binding of vascular endothelial growth factor to its kinase domain receptor.
    Hetian L, Ping A, Shumei S, Xiaoying L, Luowen H, Jian W, Lin M, Meisheng L, Junshan Y, Chengchao S.
    J Biol Chem; 2002 Nov 08; 277(45):43137-42. PubMed ID: 12183450
    [Abstract] [Full Text] [Related]

  • 9. TTAC-0001, a human monoclonal antibody targeting VEGFR-2/KDR, blocks tumor angiogenesis.
    Lee WS, Pyun BJ, Kim SW, Shim SR, Nam JR, Yoo JY, Jin Y, Jin J, Kwon YG, Yun CO, Nam DH, Oh K, Lee DS, Lee SH, Yoo JS.
    MAbs; 2015 Nov 08; 7(5):957-68. PubMed ID: 25942475
    [Abstract] [Full Text] [Related]

  • 10. Identification of novel neutralizing single-chain antibodies against vascular endothelial growth factor receptor 2.
    Erdag B, Balcioglu BK, Bahadir AO, Serhatli M, Kacar O, Bahar A, Seker UO, Akgun E, Ozkan A, Kilic T, Tamerler C, Baysal K.
    Biotechnol Appl Biochem; 2011 Nov 08; 58(6):412-22. PubMed ID: 22172104
    [Abstract] [Full Text] [Related]

  • 11. A vascular endothelial growth factor high affinity receptor 1-specific peptide with antiangiogenic activity identified using a phage display peptide library.
    El-Mousawi M, Tchistiakova L, Yurchenko L, Pietrzynski G, Moreno M, Stanimirovic D, Ahmad D, Alakhov V.
    J Biol Chem; 2003 Nov 21; 278(47):46681-91. PubMed ID: 12954624
    [Abstract] [Full Text] [Related]

  • 12. Affinity maturation and fine functional mapping of an antibody fragment against a novel neutralizing epitope on human vascular endothelial growth factor.
    Lamdan H, Gavilondo JV, Muñoz Y, Pupo A, Huerta V, Musacchio A, Pérez L, Ayala M, Rojas G, Balint RF, Larrick JW.
    Mol Biosyst; 2013 Aug 21; 9(8):2097-106. PubMed ID: 23702826
    [Abstract] [Full Text] [Related]

  • 13. Human/mouse cross-reactive anti-VEGF receptor 2 recombinant antibodies selected from an immune b9 allotype rabbit antibody library.
    Popkov M, Jendreyko N, Gonzalez-Sapienza G, Mage RG, Rader C, Barbas CF.
    J Immunol Methods; 2004 May 21; 288(1-2):149-64. PubMed ID: 15183093
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of both the autocrine and the paracrine growth of human leukemia with a fully human antibody directed against vascular endothelial growth factor receptor 2.
    Zhang H, Li Y, Li H, Bassi R, Jimenez X, Witte L, Bohlen P, Hicklin D, Zhu Z.
    Leuk Lymphoma; 2004 Sep 21; 45(9):1887-97. PubMed ID: 15223651
    [Abstract] [Full Text] [Related]

  • 15. Production of neutralizing monoclonal antibody against human vascular endothelial growth factor receptor II.
    Li R, Xiong DS, Shao XF, Liu J, Xu YF, Xu YS, Liu HZ, Zhu ZP, Yang CZ.
    Acta Pharmacol Sin; 2004 Oct 21; 25(10):1292-8. PubMed ID: 15456530
    [Abstract] [Full Text] [Related]

  • 16. Identification of the residues in the extracellular region of KDR important for interaction with vascular endothelial growth factor and neutralizing anti-KDR antibodies.
    Lu D, Kussie P, Pytowski B, Persaud K, Bohlen P, Witte L, Zhu Z.
    J Biol Chem; 2000 May 12; 275(19):14321-30. PubMed ID: 10799512
    [Abstract] [Full Text] [Related]

  • 17. Phage-derived fully human monoclonal antibody fragments to human vascular endothelial growth factor-C block its interaction with VEGF receptor-2 and 3.
    Rinderknecht M, Villa A, Ballmer-Hofer K, Neri D, Detmar M.
    PLoS One; 2010 Aug 02; 5(8):e11941. PubMed ID: 20689828
    [Abstract] [Full Text] [Related]

  • 18. Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor.
    Lu D, Jimenez X, Zhang H, Wu Y, Bohlen P, Witte L, Zhu Z.
    Cancer Res; 2001 Oct 01; 61(19):7002-8. PubMed ID: 11585724
    [Abstract] [Full Text] [Related]

  • 19. Phage-derived fully human antibody scFv fragment directed against human vascular endothelial growth factor receptor 2 blocked its interaction with VEGF.
    Zhang J, Li H, Wang X, Qi H, Miao X, Zhang T, Chen G, Wang M.
    Biotechnol Prog; 2012 Jul 01; 28(4):981-9. PubMed ID: 22581629
    [Abstract] [Full Text] [Related]

  • 20. A KDR-binding peptide (ST100,059) can block angiogenesis, melanoma tumor growth and metastasis in vitro and in vivo.
    Rastelli L, Valentino ML, Minderman MC, Landin J, Malyankar UM, Lescoe MK, Kitson R, Brunson K, Souan L, Forenza S, Goldfarb RH, Rabbani SA.
    Int J Oncol; 2011 Aug 01; 39(2):401-8. PubMed ID: 21567086
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.